Manulife’s long-term care reinsurance strategy has produced its third deal — the smallest by size, but the most instructive by design. The insurer has agreed to cede a C$3.2 billion IFRS reserve figure, calculated at an 80% quota share, on a standalone U.S. long-term care block to Munich American Reassurance Company (“Munich Re Life US”), a subsidiary of Munich Re Group, in what is Manulife’s third LTC reinsurance transaction and its first on a standalone LTC block.
The Smallest Deal, the Clearest Signal
Structurally, the agreement is a full risk transfer on the biometric risk with no transfer of assets, meaning Munich Re Life US takes on the mortality, morbidity and lapse risk embedded in the block while Manulife retains the underlying invested assets. According to the announcement filed by Manulife Financial Corporation, the deal is expected to close in Q4 2026 pending regulatory approvals. The counterparty, Munich Re Life US, is a subsidiary of Munich Re Group and a leading U.S. reinsurer with a significant market presence and extensive technical depth across life and disability reinsurance — a profile reinforced by Munich Re’s H1 2026 results, which showed the group still absorbing large blocks of long-duration life and health risk despite a heavy catastrophe year.
What a Negative Cede Actually Buys
The headline number is the smallest of Manulife’s three LTC-related transactions, but the pricing structure is the part worth reading closely. Manulife disclosed pricing similar to prior deals, with a modest negative 5% cede — language that means Manulife pays Munich Re Life US to take on the block, rather than collecting upfront proceeds for offloading a distressed liability. That is not a symptom of weak reserves: the company said the transaction is largely neutral to capital, with an immaterial annual impact to both core earnings and net income attributed to shareholders of approximately $30 million in the first year and reducing over time. Together, a negative cede and capital neutrality look less like risk offloading and more like a paid-for second opinion: Manulife is buying independent validation of its LTC reserves and morbidity assumptions from a reinsurer with deep actuarial expertise, while keeping the balance-sheet impact close to nil. The transaction’s figures are based on Manulife’s June 30, 2026 position and are expressed in Canadian dollars at an exchange rate of US$1.00 to C$1.41875 — the reason the headline C$3.2 billion figure should not be read as a U.S.-dollar amount.
Three Deals, One Shrinking Morbidity Tail
This is Manulife’s third pass at LTC biometric risk in under three years, and the pattern is cumulative, not one-off. The first was $13 billion reinsurance transaction, including $6 billion of LTC, with Global Atlantic that was announced in December 2023 and closed in February 2024. The second was the $5.4 billion reinsurance transaction with RGA, including $2.4 billion of LTC, announced in November 2024 and closed in January 2025. Munich Re Life US is now the third counterparty in as many years, and Manulife frames the sequence as one de-risking program, not three unrelated trades: upon closing, the company will have cumulatively reduced LTC morbidity sensitivity by 24% across all three transactions. President and chief executive Phil Witherington tied the deal to that broader pattern, saying today’s announcement represents the company’s third LTC reinsurance transaction in under three years and first on a standalone LTC block, reflecting its ability to reduce its risk profile and strengthen its business through innovative actions. The shift from bundled deals to a standalone LTC cession is notable: reinsurers are now willing to underwrite LTC morbidity risk on its own terms, not only packaged with more diversified blocks. Manulife is not the only carrier moving legacy reserves off its books this year; another North American carrier ceding legacy reserves struck a comparable deal on guaranteed universal life exposure earlier in 2026, part of a broader wave of reserve cessions crossing product lines.
Better Morbidity Data, Harder-Nosed Pricing
The willingness of reinsurers to price standalone LTC risk on ordinary terms is tied to how much better the underlying data has become. LTC has long been a notoriously difficult line to underwrite: the NAIC’s long-term care insurance topic page notes that in 2010, U.S. spending on long-term care services was about 1% of gross domestic product, and that the market has consolidated sharply since insurers first misjudged morbidity assumptions: there are now 100 companies that offer LTC insurance nationally, but only 15 to 20 insurers sell most policies. That consolidation is now followed by a data upgrade. In 2025, LIMRA, the Society of Actuaries Research Institute, and the NAIC jointly announced the launch of a long-term care insurance industry experience study, according to the NAIC’s announcement of the study’s launch. The study will examine mortality, persistency, claim incidence and claim termination experience for LTC insurance policies from 2000 through 2023, with 13 carriers representing two-thirds of the standalone LTC insurance market participating. Better morbidity data is what lets a reinsurer accept a negative cede on confidence rather than a distress discount. LTC repricing pressure is not confined to North America: demographic strain is forcing similar recalibration abroad, most visibly where population decline is pushing insurers to revisit longevity and LTC assumptions altogether.
